Technical Data
G8951-25M
Granulocyte Macrophage Colony Stimulating Factor, Recombinant, Mouse (GM-CSF, Colony-stimulating Factor, CSF, Colony Stimulating Factor 2 (Granulocyte-macrophage), Csf2, Csfgm, MGC151255, MGC151257, MGI-IGM)
10ug
Molecular Biology Storage: -20CShipping: Blue Ice
Source:
Recombinant corresponding to 125aa of mouse Granulocyte Macrophage-Colony Stimulating Factor expressed in E.coli is a single, non-glycosylated, polypeptide chain.

Molecular Weight:
~14.3kD

Biological Activity:
The ED50 as determined by the dose-dependent stimulation of the proliferation of mouse FDC-P1 cell line is less then 0.2ng/ml, corresponding to a Specific Activity of 5x10 6IU/mg.

Dimers and Aggregates:
1% (SDS-PAGE)

Protein Content:
Protein quantitation was carried out by two independent methods: 1.UV spectroscopy at 280nm using the absorbency value of 0.765 as the extinctioncoefficient for a 0.1% (1mg/ml) solution. This value is calculated by the PC GENEcomputer analysis program of protein sequences (IntelliGenetics). 2. Analysis by RP-HPLC, using a standard solution of GM-CSF as a Reference Standard.

Storage and Stability:
Lyophilized powder may be stored at -20C. Stable for 12 months at -20C. Reconstitute with sterile ddH2O, HSA or BSA. Aliquot to avoid repeated freezing and thawing. Store at -20C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.

Molecular Weight:
~14.3kD
Purity: ~98% (RP-HPLC, Anion-exchange FPLC, SDS-PAGE) Endotoxin: 0.1ng/ug (IEU/ug)
Concentration: Not determined
Form: Supplied as a lyophilized powder. No preservative added. Reconstitute with sterile dH2O, 0.1% HSA or BSA to 0.1mg/ml.

Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.
1. In vitro effector activity of Pneumocystis murina-specific T-cytotoxic-1 CD8+ T cells: role of granulocyte-macrophage colony-stimulating factor. Infect Immun 2005 Nov;73(11):7450-7. 2. Serum profiles of circulating granulocyte-macrophage colony-stimulating factor in acute myocardial infarction and relation with post-infarction left ventricular function. Chin Med J (Engl) 2005 Sep 20;118(18):1557-9. 3. Comparison of the activities of granulocyte-macrophage colony-stimulating factor and interleukin-8 secretion between two lung epithelial cell lines. J Microbiol Immunol Infect 2005 Oct;38(5):327-31. 4. Nonobese diabetic mouse congenic analysis reveals chromosome 11 locus contributing to diabetes susceptibility, macrophage STAT5 dysfunction, and granulocyte-macrophage colony-stimulating factor overproduction. J Immunol 2005 Oct 1;175(7):4561-5. 5. Low-dose cytosine arabinoside (LD-AraC) vs LD-AraC plus granulocyte/macrophage colony stimulating fact or vs LD-AraC plus Interleukin-3 for myelodysplastic syndrome patients with a high risk of developing acute leukemia: final results of a randomized phase III study (06903) of the EORTC Leukemia Cooperative Group. Leukemia 2005 Nov;19(11):1929-33. 6. [Granulocyte-macrophage colony-stimulating factor]. Nippon Rinsho 2005 Aug;63 Suppl 8:51-3.

Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.